PetMedix Ltd.

Based in Babraham, Cambridge, UK, PetMedix specializes in developing biopharmaceuticals for the veterinary market, focusing on innovative therapies for companion animals. Founded in 2017, PetMedix develops biopharmaceuticals specifically for pets. The company has not undergone notable pivots or changes in strategy. The founders include Allan Bradley and Thomas 文腾仕, with Thomas 文腾仕 also serving as the CEO.

PetMedix has raised a total of USD 111. 00 mn, with its latest funding round being a Trade Sale to Zoetis Inc on 2023-09-15. PetMedix specializes in developing and commercializing biopharmaceuticals for the veterinary market, focusing primarily on providing innovative therapies for companion animals. Their core product offerings include monoclonal antibodies that are designed to treat various diseases in pets, including cancer and autoimmune disorders.

These biologics are formulated to enhance animal health and increase the quality of life for pets suffering from complex conditions. The company targets veterinarians and pet owners as its primary customer base, ensuring that the end users—companion animals—receive effective treatments tailored to their specific health needs. PetMedix's products are sold primarily in the United Kingdom and Europe, where the demand for advanced veterinary therapeutics is steadily rising. PetMedix generates revenue through a combination of direct sales and strategic partnerships with veterinary clinics and animal health distributors.

The company engages in B2B transactions, supplying its pharmaceutical products directly to veterinary practices and leveraging relationships with wholesalers to reach a broader market. Revenue is structured around the sales of their flagship products, which are expected to be priced competitively in the biopharmaceutical sector. This transactional framework allows PetMedix to maintain a steady income stream while also facilitating the availability of their innovative veterinary treatments to a wide range of practitioners and pet owners. In September 2023, Zoetis Inc acquired PetMedix Ltd.

for USD 111. 00 mn, which includes an additional payment of approximately USD 100 mn based on achieving certain milestones. This acquisition enables Zoetis Inc to enhance its research capabilities and accelerate the development of monoclonal antibody therapies for pets. Plans include the design and launch of new products targeting unmet medical needs in the pet population, as well as potential expansion into new geographic markets, with a focus on Europe and North America in the coming years.